PET inaccurately suggested radiation necrosis; two patients with newly diagnosed enhancing lesions on MRI in whom PET was useful in distinguishing strokes from tumour; two patients with prior gliomas with new enhancing isolated lesions on MRI in whom PET scan accurately depicted radiation necrosis; and two patients with newly diagnosed enhancing lesions on MRI in whom PET scan was helpful in distinguishing multiple sclerosis from tumour in one but not in the other. Therefore, of the 39 patients, PET was helpful in five in distinguishing tumour from other disease processes; but, in so far as influencing treatment, it seemed helpful in only two.
Thus PET seems to be of limited value as an aid to evaluating and treating patients with suspected or known primary brain tumours. ( 
Results
We divided the patients into two groups. In the first group (30 patients) were those in whom MRI and PET concurred on the diagnosis. These included nine patients with low grade tumours where the MRI was interpreted as low grade glioma, postoperative change, or recurrent low grade glioma and PET was hypometabolic in the region of the tumour. These patients have all had stable clinical courses or have been reoperated on and had confirmed low grade tumours. Twenty patients have had MRI interpreted as recurrent or residual high grade tumour or increase in tumour grade, and these patients have shown hypermetabolism on PET. One patient with a high grade glioma has had MRI and PET that showed no residual tumour six years after operation. Although PET offered confirmatory data in these patients, it did not seem to alter the clinical course or treatment regimen.
Most patients with recurrent high grade tumour or increase in tumour grade died fairly soon after this diagnosis was made (average six months). The decision to reoperate was made on whether the recurrence was in an accessible area, was causing mass effect, and on the preoperative Karnofsky score. The PET results did not seem to influence that decision. As far as influencing the decision to give chemotherapy, most of the young patients were already on some chemotherapeutic regimen or, especially in elderly patients, it was considered that chemotherapy would not be helpful.
In nine patients, the interpretations of MRI and PET were different or there was a question of the diagnosis on MRI. Three patients with known primary gliomas, all previously operated on and given radiotherapy, had a deterioration in clinical state and an MRI consistent with recurrent high grade tumour (or increase in tumour grade). The PET scan was thought to be consistent with radiation necrosis. Two of these three had high grade tumours confirmed by biopsy. One had a subsequent PET that showed hypermetabolism, consistent with a recurrent tumour.
Two patients with previous surgery and radiotherapy for glioma had MRI with contrast enhancing lesions without significant mass effect. A PET scan showed hypometabolism in these regions, indicative of radiation necrosis. One patient has been stable and the other has had a slow clinical deterioration over several years, so although helpful, PET did not influence treatment. There were four patients with newly diagnosed enhancing lesions on MRI in whom PET was done because of the clinical suspicion that these lesions were not tumours although tumour was the differential diagnosis on MRI. Two patients, both with biopsy proved multiple sclerosis, had PET. The follow up postoperative scan of one patient showed that the enhancing lesion had increased in size. This patient had had a previous craniotomy for a presumed glioma. Consideration was given to rebiopsy because of the possibility that the first biopsy was in error, but PET showed a hypometabolic lesion. With increased steroid dosage the lesion has essentially resolved, and the patient has been stable clinically. The other patient had an enhancing lesion on MRI and hypermetabolism on PET suggestive of a tumour. A stereotaxic biopsy showed demyelinating disease and the patient has improved with steroid medication. In one of these patients, the results of PET were useful in obviating the need for rebiopsy.
Two patients with the clinical presentation of stroke had enhancing lesions on MRI; PET showed hypometabolism and the clinical course and subsequent MRI have been consistent with stroke. In one of these patients, with a thalamic lesion, stereotaxic biopsy was considered but PET obviated the need for this. Therefore, it was considered that PET was helpful in five patients (one with multiple sclerosis, two with radiation necrosis, two with stroke) in distinguishing tumour from other disease processes. In so far as influencing treatment, however, it seemed useful in one patient with multiple sclerosis and one patient with a thalamic stroke. Table 1 summarises the PET and MRI findings.
Discussion
The usefulness of a diagnostic test depends on its accuracy, whether other available tests give the same or better information, and whether the information obtained will influence treatment decisions or the ultimate prognosis of the patient. Data on the accuracy of PET in brain gliomas is still forthcoming. In the original paper by DiChiro et al, all 10 patients with high grade astrocytomas showed a region of high activity and a visible hot spot and none of the 13 patients with low grade gliomas showed this. All cases were, however, not proved by biopsy. Others have reported varying degrees of accuracy of PET in differentiating high grade from low grade tumours and high grade tumours from radiation necrosis.' Valk et al studied the use of PET in malignant cerebral tumours after interstitial brachytherapy.5 The overall accuracy of PET for differentiating tumour recurrence from absence of active tumour was 85%. Sensitivity for detection of recurrence was 88% and specificity 81%. Of note, histological examination of the resected tissues showed apparently viable tumour in all of the cases regardless of the eventual clinical outcome or PET results. Our experience is similar to others in that most 
